Polar Asset Management Partners Inc. Acquires Shares of 124,900 BioNTech SE (NASDAQ:BNTX)

Polar Asset Management Partners Inc. bought a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 124,900 shares of the company's stock, valued at approximately $14,834,000. Polar Asset Management Partners Inc. owned 0.05% of BioNTech as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the company. Baillie Gifford & Co. lifted its holdings in shares of BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock valued at $986,750,000 after buying an additional 31,773 shares during the period. FMR LLC lifted its holdings in shares of BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company's stock valued at $748,243,000 after buying an additional 5,598,190 shares during the period. Deerfield Management Company L.P. Series C lifted its holdings in shares of BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company's stock valued at $47,734,000 after buying an additional 24,426 shares during the period. Candriam S.C.A. lifted its holdings in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock valued at $46,526,000 after buying an additional 418,695 shares during the period. Finally, Fred Alger Management LLC acquired a new stake in shares of BioNTech in the 3rd quarter valued at approximately $59,485,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Stock Down 0.8 %

Shares of NASDAQ BNTX traded down $0.89 on Wednesday, hitting $114.70. The company had a trading volume of 417,333 shares, compared to its average volume of 812,379. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The business has a 50 day moving average of $113.83 and a two-hundred day moving average of $99.12. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $27.50 billion, a P/E ratio of -54.90 and a beta of 0.22.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same quarter in the prior year, the business earned $0.73 earnings per share. The company's revenue was up 38.9% compared to the same quarter last year. As a group, equities research analysts forecast that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BNTX has been the subject of several research analyst reports. JPMorgan Chase & Co. dropped their price objective on BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a research note on Tuesday, November 26th. Jefferies Financial Group raised BioNTech from a "hold" rating to a "buy" rating and raised their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft lifted their price objective on BioNTech from $95.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, September 19th. HC Wainwright reiterated a "buy" rating and issued a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Finally, Morgan Stanley upgraded BioNTech from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $138.67.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.